US Molecular Diagnostics Market (2025-2030)
The US Molecular Diagnostics Market was valued at $5082.5 Million in 2025 and projected to reach to $8142 Million by 2030, representing a compound annual growth rate of 9.9%. The US molecular diagnostics market is poised for sustained growth through 2030, reaching $8,142 million as healthcare providers increasingly integrate precision medicine into clinical practice.
US Molecular Diagnostics Market Trends and Insights
- This growth trajectory reflects the US healthcare system's increasing adoption of precision medicine and advanced diagnostic technologies.
- The US market benefits from strong healthcare infrastructure, significant R&D investment, and rising demand for early disease detection across oncology, infectious disease, and genetic testing applications. Driving the US market's 9.9% compound annual growth rate are factors including the proliferation of next-generation sequencing platforms, expanding reimbursement coverage, and heightened consumer awareness of personalized medicine.
- The US regulatory environment, led by the FDA, continues to streamline approval pathways for innovative molecular diagnostic assays.
- Healthcare providers across the US are increasingly integrating molecular testing into standard clinical protocols, supported by growing evidence of improved patient outcomes and cost-effectiveness..
Key Market Statistics
- CAGR (2025-2030) 9.9% CAGR
- Market Size, 2025 ~USD 5082.5 Million
- Forecast, 2030 ~USD 8142 Million
- Country US
US Molecular Diagnostics Market Overview
Market Valuation :
The US molecular diagnostics market is valued at $5,082.5 million in 2025, demonstrating strong market maturity and significant healthcare spending on advanced diagnostic solutions.
Robust Growth Trajectory :
With a CAGR of 9.9% through 2030, the US market is expanding faster than the global average of 9.6%, driven by precision medicine adoption and technological innovation.
Healthcare Infrastructure Advantage :
The US benefits from world-class healthcare infrastructure, substantial R&D investments, and regulatory frameworks that accelerate the commercialization of molecular diagnostic technologies.
Precision Medicine Demand :
Rising adoption of personalized medicine approaches and increasing patient awareness of genetic testing are fueling demand for molecular diagnostics across US healthcare systems.
US Molecular Diagnostics Market Dynamics
- This expansion is supported by favorable reimbursement policies, growing insurance coverage for genetic testing, and the proliferation of point-of-care molecular diagnostic devices.
- The US market's maturity and high healthcare expenditure create opportunities for both established players and innovative startups. Key drivers include rising cancer incidence requiring molecular profiling, infectious disease surveillance needs, and the shift toward preventive healthcare.
- Investment in genomic research infrastructure and partnerships between diagnostic companies and healthcare systems will further accelerate market penetration.
- The competitive landscape remains dynamic, with continuous technological advancement and consolidation shaping the market's evolution through the forecast period..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Stryker Corporation
- Abbott Laboratories
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- The US molecular diagnostics market will grow from $5,082.5M (2025) to $8,142M (2030), representing a 9.9% CAGR.
- The US market is driven by adoption of precision medicine, NGS platforms, and expanded reimbursement policies.
- The US regulatory landscape supports innovation through FDA streamlined approval pathways for molecular assays.
- Healthcare providers across the US are integrating molecular testing into standard clinical protocols for improved patient outcomes.
Molecular Diagnostics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | HEPATITIS (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 9.6% from 2025 to 2030 |
| Largest Segment | LAB TESTS (Test Type) |
| Market Size Base Year (Billions) | ~USD 19.44 (2025) |
| Revenue Forecast (Billions) | ~USD 30.74 (2030) |
| Segments Covered | Product & Service, Test Type, Sample Type, Type |
US Molecular Diagnostics Market Report Segmentation
4 segment dimensions are covered across the global market.
By Product & Service
- Instruments
- Reagents & Kits
- Services & Software
By Test Type
- Lab Tests
- Poc Tests
By Sample Type
- Blood, Serum & Plasma
- Other Sample Types
- Urine
By Type
- Breast Cancer
- Colorectal Cancer
- Influenza
- Lung Cancer
- Other Cancers
- Other Respiratory Infectious Diseases
- Pharyngitis
- Prostate Cancer
- Tuberculosis
Target Audience
- Diagnostic Device Manufacturers : Manufacturers need US market data to benchmark performance, identify growth opportunities, optimize product portfolios, and develop market entry or expansion strategies.
- Healthcare System Administrators : Hospital networks and healthcare systems require market insights to make informed procurement decisions, budget allocations, and technology adoption strategies for molecular diagnostics.
- Investment & Private Equity Firms : Investors need comprehensive US market analysis to evaluate acquisition targets, assess portfolio company performance, and identify emerging opportunities in molecular diagnostics.
- Pharmaceutical & Biotech Companies : Pharma companies require market intelligence to support companion diagnostic development, clinical trial planning, and commercialization strategies in the US market.
- Healthcare Consultants & Analysts : Consultants and research analysts need detailed US market data to support client advisory work, competitive analysis, and strategic recommendations in precision medicine.
Key Companies in the US Molecular Diagnostics Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CEPHEID INC. | United States | Private Company | GeneXpert instruments,Xpert test cartridges (infectious disease and HAIs),Virology, oncology, and genetics assays, |
| FLUOR CORPORATION | United States | Public Company | Energy Solutions (oil, gas, chemicals, LNG, power, energy transition),Urban Solutions (advanced technologies, life sciences, mining, infrastructure, staffing, maintenance),Mission Solutions (government, nuclear remediation, logistics, O&M, mission-critical facilities), |
| SANOFI | France | Public Company | Pediatric and combination vaccines (polio, pertussis, Hib, hexavalent),Other vaccines (RSV, hepatitis A, typhoid, yellow fever, rabies),Immunology and inflammation therapies, |
| CODEXIS, INC. | United States | Public Company | CodeEvolver-enabled enzyme products and services,ECO Synthesis RNAi manufacturing platform (licenses, milestones, royalties),Other technology partnerships and R&D collaborations, |
| UNILABS | Switzerland | Private Company | Core laboratory testing,Medical imaging,Pathology and centres of excellence, |
| EIKEN CHEMICAL CO., LTD. | Japan | Public Company | Fecal immunochemical test (FIT) reagents and analyzers,Microbiological reagents and media (clinical),Urinalysis test strips, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology,Life Sciences,Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array instruments and consumables, |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, viral load, SARS-CoV-2),Breast Health (3D mammography, biopsy, localization, treatment support),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa ProVu, CoolSeal), |
| BIOMÉRIEUX | France | Public Company | |
| ABBOTT LABORATORIES | United States | Public Company | Medical Devices (cardiovascular, diabetes care, neuromodulation),Diagnostic Products (lab, molecular, point-of-care, rapid),Nutritional Products (pediatric, adult, infant formula), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| QIAGEN N.V. | Netherlands | Public Company | Sample technology consumables and instruments,Immune response (TB and transplant/viral load assays),Oncology and sexual and reproductive health assays, |
| REVVITY, INC. | United States | Public Company | Diagnostics (prenatal, neonatal, infectious disease, autoimmune),Life science reagents and assay platforms,Instruments, software, and services, |
| GRIFOLS, S.A. | Spain | Public Company | Biopharma (plasma-derived medicines),Diagnostic,Bio Supplies, |
CEPHEID INC.
Cepheid Inc. is a private U.S. diagnostic company founded in 1996 with 1,700 employees. The company specializes in molecular diagnostics and infectious disease testing solutions.
FLUOR CORPORATION
Fluor Corporation is a large U.S. engineering and construction company founded in 1912, operating as a public company with approximately 23,000 employees. The firm provides design, engineering, procurement, and construction services across multiple industries.
SANOFI
Sanofi is a major French pharmaceutical company founded in 1994 and publicly traded, with over 74,800 employees worldwide. The company develops and manufactures prescription medicines, vaccines, and consumer healthcare products.
CODEXIS, INC.
Codexis, Inc. is a publicly traded U.S. biotechnology company founded in 2002 with 146 employees. The company develops and commercializes biocatalysts and enzymes for pharmaceutical and chemical manufacturing.
UNILABS
Unilabs is a private Swiss clinical laboratory and diagnostics company founded in 1987 with 1,897 employees. The company offers laboratory testing and diagnostic services across Europe.
EIKEN CHEMICAL CO., LTD.
Eiken Chemical Co., Ltd. is a publicly traded Japanese chemical and diagnostics company founded in 1939 with 696 employees. The company manufactures diagnostic reagents, pharmaceuticals, and chemical products.
DANAHER CORPORATION
Danaher Corporation is a large publicly traded U.S. conglomerate founded in 1969 with 59,000 employees. The company operates across multiple sectors including diagnostics, life sciences, and environmental solutions.
ILLUMINA, INC.
Illumina, Inc. is a publicly traded U.S. genomics company founded in 1998 with 8,625 employees. The company designs and manufactures DNA sequencing and array-based analysis systems.
HOLOGIC, INC.
Hologic, Inc. is a private U.S. medical device company founded in 1985 with 7,070 employees. The company develops and manufactures diagnostic and surgical products focused on women's health and oncology.
BIOMÉRIEUX
bioMérieux is a publicly traded French diagnostics company founded in 1963 with 14,894 employees. The company specializes in in vitro diagnostics for infectious diseases, industrial microbiology, and food safety.
ABBOTT LABORATORIES
Abbott Laboratories is a large publicly traded U.S. healthcare company founded in 1888 with 115,000 employees. The company manufactures pharmaceuticals, diagnostics, medical devices, and nutritional products.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a major publicly traded U.S. life sciences company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, software, and services for research and diagnostics.
QIAGEN N.V.
QIAGEN N.V. is a publicly traded Dutch life sciences company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics, sample preparation, and bioinformatics solutions.
REVVITY, INC.
Revvity, Inc. is a publicly traded U.S. life sciences and diagnostics company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for research and diagnostics.
GRIFOLS, S.A.
Grifols, S.A. is a publicly traded Spanish pharmaceutical and diagnostics company founded in 1909 with 25,000 employees. The company specializes in plasma-derived medicines, transfusion medicine, and diagnostics.
Reasons to Buy this Report
- Market Size & Growth Data : Access precise valuation figures for the US market ($5.1B in 2025) and detailed forecasts through 2030, enabling accurate financial planning and investment decisions.
- Competitive Landscape Intelligence : Understand the US-specific competitive dynamics, key players, market consolidation trends, and strategic positioning within the world's largest molecular diagnostics market.
- Regulatory & Reimbursement Insights : Gain detailed analysis of US FDA regulations, insurance coverage policies, and reimbursement trends that directly impact market accessibility and revenue potential.
- Technology & Application Trends : Identify emerging molecular diagnostic technologies, clinical applications, and adoption patterns specific to US healthcare systems and patient populations.
- Strategic Market Opportunities : Discover high-growth segments, underserved clinical areas, and geographic hotspots within the US market for targeted expansion and partnership development.
Frequently asked questions
What is the current size of the US molecular diagnostics market?
The US molecular diagnostics market is valued at $5,082.5 million in 2025 and is expected to grow to $8,142 million by 2030.
What is the projected growth rate for the US molecular diagnostics market?
The US molecular diagnostics market is projected to grow at a compound annual growth rate (CAGR) of 9.9% from 2025 to 2030.
What are the primary drivers of growth in the US molecular diagnostics market?
Key drivers include increased adoption of precision medicine, proliferation of next-generation sequencing technologies, expanding insurance reimbursement, and growing demand for early disease detection in the US.
Which disease segments are driving demand in the US molecular diagnostics market?
The US market is experiencing strong demand across oncology, infectious disease diagnostics, and genetic testing applications, with healthcare providers increasingly adopting molecular testing for improved patient outcomes.
How does the US regulatory environment support molecular diagnostics growth?
The US FDA has implemented streamlined approval pathways for innovative molecular diagnostic assays, facilitating faster market entry and supporting the expansion of molecular testing in US healthcare settings.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the global molecular diagnostics market. Exhaustive secondary research was done to collect information on the molecular diagnostics market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the molecular diagnostics market.
The four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to, to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources mainly include industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
Breakdown Of Primary Participants
Note 1: Others include Sales Managers, Marketing Managers, and Product Managers.
Note 2: Companies are classified into tiers based on their total revenue. Here’s the breakdown of tiers:
Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate and validate the molecular diagnostics market’s total size. These methods were also used extensively to estimate the size of various subsegments in the market.
- The key players in the industry have been identified through extensive secondary research.
- Primary and secondary research have determined the revenues generated by leading players operating in the molecular diagnostics market.
- All percentage share, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Molecular diagnostics is a technique used to identify and analyze nucleic acids or proteins at a molecular level. This technique assesses an individual’s genetic makeup to identify a predisposition to any particular disease or condition and diagnose it.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global molecular diagnostics market by product & service, test type, sample type, technology, application, technique, clinical application, end user, and region
- To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
- To analyze the micromarkets concerning individual growth trends, prospects, and contributions to the overall molecular diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market with respect to five regions, namely North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments, such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the molecular diagnostics market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the molecular diagnostics market, along with the macroeconomic outlook for each region
Get the Full Molecular Diagnostics Market Report
Full forecast, segment splits, and company analysis for all Molecular Diagnostics Market.
- Canada Molecular Diagnostics Market
- Germany Molecular Diagnostics Market
- UK Molecular Diagnostics Market
- France Molecular Diagnostics Market
- Italy Molecular Diagnostics Market
- Spain Molecular Diagnostics Market
- Russia Molecular Diagnostics Market
- Switzerland Molecular Diagnostics Market
- China Molecular Diagnostics Market
- Japan Molecular Diagnostics Market
- India Molecular Diagnostics Market
- Australia Molecular Diagnostics Market
- South Korea Molecular Diagnostics Market
- Brazil Molecular Diagnostics Market
- Mexico Molecular Diagnostics Market
- Saudi Arabia Molecular Diagnostics Market
- UAE Molecular Diagnostics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report